A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer(WJOG10417GTR)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 Results of a biomarker analysis assessing IL33-ST2 axis as a diagnostic and therapeutic biomarker in nivolumab therapy for advanced gastric cancer, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
21 Jan 2023 Results of a biomarker analysis assessing LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer presented at the 2023 Gastrointestinal Cancers Symposium
13 Sep 2022 Results (between August 2018 and November 2020) assessing the prognostic impact of these subsets remains to be determined, particularly in advanced gastric cancer patients receiving nivolumab monotherapy that provides limited efficacy, presented at the 47th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com